Cytapheresis in patients with severe ulcerative colitis after failure of intravenous corticosteroid: A Long-Term retrospective cohort study

Gut and Liver

Volumn 3, Issue 1, 2009, Pages 41-47

  Fukunaga, Ken ^a   Nagase, Kazuko ^a   Kusaka, Takeshi ^a   Hida, Nobuyuki ^a   Ohda, Yoshio ^a   Yoshida, Koji ^a   Tozawa, Katsuyuki ^a   Kamikozuru, Koji ^a   Iimuro, M ^a   Nakamura, Shiro ^a   Miwa, Hiroto ^a   Matsumoto, Takayuki ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Corticosteroid; Inflammatory bowel disease; Leukapheresis; Ulcerative colitis

Indexed keywords

MESALAZINE; PREDNISOLONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLON RESECTION; CONTROLLED STUDY; CYTAPHERESIS; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG TREATMENT FAILURE; DYSPNEA; FEMALE; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; HUMAN; LOW DRUG DOSE; MALE; NAUSEA; RETROSPECTIVE STUDY; ULCERATIVE COLITIS;

EID: 67249148446     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl.2009.3.1.41     Document Type: Article

References (37)

1. Allison MC, Dhillon AP, Lewis WG, Pounder RE. Inflammatory bowel disease. London: Mosby, 1998:9-95.
2. Truelove SC, Willoughby CP, Lee EG, Kettlewell MG. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet 1978;2:1086-1088. (Pubitemid 9052873)
3. Lichtiger S, Present DH, Kornbluth A. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-1845.
4. Serkova NJ, Christians U, Benet LZ. Biochemical mechanisms of cyclosporine neurotoxicity. Mol Interv 2004;4:97-107.
5. Present DH. How to do without steroids in inflammatory bowel disease. Inflamm Bowel Dis 2000;6:48-57.
6. Sawada K, Ohnishi K, Fukui S, et al. Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel disease. J Gastroenterol 1995;30:322-329.
7. Sawada K, Muto T, Shimoyama T, et al. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a Leukocytapheresis column. Curr Pharm Des 2003;9:307-321.
8. Shimoyama T, Sawada K, Hiwatashi N, et al. Safety and efficacy of granulocytes and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apher 2001;16:1-9.
9. Kanai T, Hibi T, Watanabe M. The logics of leukocytapheresis as a natural biological therapy for inflammatory bowel disease. Expert Opin Biol Ther 2006;6:453-466. (Pubitemid 43723295)
10. Hanai H. Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis. World J Gastroenterol 2006;12:7568-7577. (Pubitemid 46040566)
11. Saniabadi AR, Hanai H, Takeuchi K, et al. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial 2003;7:48-59.
12. Saniabadi AR, Hanai H, Fukunaga K, et al. Therapeutic leukocytapheresis for inflammatory bowel disease. Transfus Apher Sci 2007;37:191-200.
13. Matts SG. The value of rectal biopsy in the diagnosis of ulcerative colitis. Q J Med 1961;30:393-407. (Pubitemid 33115861)
14. Jarnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985;89:1005-1013. (Pubitemid 16231562)
15. Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974;1:1067-1070.
16. Sawada K, Kusugami K, Suzuki Y, et al. Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am J Gastroenterol 2005;100:1362-1369.
17. Campbell S, Travis S, Jewell D. Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur J Gastroenterol Hepatol 2005;17:79-84. (Pubitemid 40128931)
18. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999;94:1587-1592. (Pubitemid 29260450)
19. D'Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroid as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001;120:1323-1329.
20. Rayner CK, McCormack G, Emmanuel AV, Kamm MA. Long-term results of low-dose intravenous ciclosporin for acute severe ulcerative colitis. Aliment Pharmacol Ther 2003;18:303-308. (Pubitemid 37046709)
21. Van Assche G, D'Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003;125:1025-1031.
22. Domenech E, Garcia-Planella E, Bernal I, et al. Azathioprine without oral cyclosporine in the long-term maintenance of remission induced by intravenous cyclosporine in severe, steroid-refractory ulcerative colitis. Aliment Pharmacol Ther 2002;16:2061-2065.
23. Tanaka T, Okanobu H, Yoshimi S, et al. In patients with ulcerative colitis, adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naive patients. Dig Liver Dis 2008;40:731-736.
24. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:15-22. (Pubitemid 30452574)
25. Hanai H, Watanabe F, Takeuchi K, et al. Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin Gastroenterol Hepatol 2003;1:28-35.
26. McCarthy DA, Rampton DS, Liu YC. Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. Clin Exp Immunol 1991;86:489-493.
27. Rugtveit J, Brandtzaeg P, Halstensen TS, Fausa O, Scott H. Increased macrophage subset in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes. Gut 1994;35:669-674. (Pubitemid 24163796)
28. Meuret G, Bitzi A, Hammer B. Macrophage turnover in Crohn's disease and ulcerative colitis. Gastroenterology 1978;74:501-503. (Pubitemid 8276540)
29. Brannigan AE, O'Connell PR, Hurley H, et al. Neutrophil apoptosis is delayed in patients with inflammatory bowel disease. Shock 2000;13:361-366.
30. Cassatella MA. The production of cytokines by polymorphonuclear neutrophils. Immunol Today 1995;16:21-26.
31. Nikolaus S, Bauditz J, Gionchetti P, Witt C, Lochs H, Schreiber S. Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin-10 during intestinal inflammation. Gut 1998;42:470-476. (Pubitemid 28186561)
32. Mahida YR. The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm Bowel Dis 2000;6:21-33.
33. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006;12 Suppl 1:S3-9.
34. Actis GC, Fadda M, David E, Sapino A. Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study. BMC Gastroenterol 2007;7:13. (Pubitemid 46604973)
35. Cohen RD. Treating ulcerative colitis without medications-"look mom, no drugs!" Gastroenterology 2005; 128:235-236.
36. Sands BE, Sandborn WJ, Feagan B, et al. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology 2008;135:400-409.
37. Hanai H. Leucocytapheresis for inflammatory bowel disease in the era of biologic therapy. Eur J Gastroenterol Hepatol 2008;20:596-600.